Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

NCT06057194 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Infections, Cytomegalovirus

Interventions

DRUG: Letermovir 240 mg Oral Tablet

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Collaborators

[object Object]